Αρχική World News Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint Inhibitor...

Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint Inhibitor Treatment in Patients with Non-Small Cell Lung Cancer

Patients with non-small cell lung cancer (NSCLC) and pleural effusion (PE), especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors (ICIs) according to findings presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

Nicolas Epaillard of the Oncology, Hopital Européen Georges Pompidou in Paris, France and colleagues explained that the pleura is a common site of metastatic involvement in patients with NSCLC and the pleura also acts as a natural barrier that can limit the penetration and efficacy of ICI, which led to the PLUIE study assessment of the clinical outcome of PE in patients with NSCLC who were treated with an ICI.

This multicentre international retrospective study identified 538 patients with NSCLC who were treated with an ICI from November 2012 to November 2019. The investigators stratified this cohort by PE (n=196) versus non-PE (n=342) as of the immunotherapy baseline.

Overall survival (OS) and the early death rate served as the primary endpoints while the secondary outcomes were progression-free survival (PFS) and the disease control rate (DCR). The association between outcomes and PE was evaluated using logistic regression, whereas univariate and multivariate Cox models were performed for OS and PFS.

The median patient age in the overall population was 62.9 years, 34.6% of patients were female, 9.5% were never smokers, and 75.7% of patients had non-squamous NSCLC. The characteristics were similar in the PE group: the patients’ median age was 64.4 years, 31.6% were female, 12.4% were never smokers, and 77.6% had non-squamous NSCLC. ICI was administered as first- or second-line in 66% of patients and 94% of patients received the ICI as monotherapy.

In terms of patient characteristics, an association was found between PE and a higher number of metastatic sites: the PE cohort had a median of 3.5 metastatic sites compared to a median 2.7 metastatic sites in the non-PE cohort. PE also associated with poorer ECOG performance status (PS): 90.8% of PE patients versus 80.5% of non-PE patients had PS ≥2.  

Overall survival was significantly shorter in PE patients compared to non-PE patients

Regarding the primary objective, the overall cohort demonstrated median OS of 9.7 months (95% confidence interval [CI] 8.1-11.8), whereas the PE cohort had a median OS of 6.3 months (95% CI 4.0-8.6) compared to 11.4 months (95% CI 9.7-13.8) in the non-PE cohort (p = 0.002). The early death rate was 31.4% in the overall cohort, while the early death rates in the PE compared to non-PE cohorts were 38.3% versus 27.5% (odds ratio [OR] 1.63; 95% CI 1.13-2.37; p = 0.01). 


Response endpoints according to the presence of pleural effusion.

© Nicolas Epaillard.

PFS, a secondary endpoint, was 1.8 months (95% CI 1.7-2.5) in the PE cohort compared to 2.3 months (95% CI 2.0-3.6) in the non-PE group (p = 0.04).

PE was a consistent independent prognostic factor for survival across adjusted analyses

Following adjustment for PS, liver, intracranial, or bone metastasis, the immunotherapy line, and the derived neutrophil to lymphocyte ratio (dNLR), PE remained an independent prognostic factor for OS (hazard ratio [HR] 1.38; 95% CI 1.09-1.74; p = 0.007) and PFS (HR 1.35, 95% CI 1.09-1.68; p = 0.006).

The DCR was 49.9% in the PE compared to 52.3% in non-PE patients (OR 1.64; 95% CI 1.14-2.40, p = 0.01).

Of the 196 patients in the PE cohort, 73 (37.2%) patients required pleural evacuation, which was associated with a significantly increased early death rate of 52% in pleural evacuated patients versus 30.5% in non-evacuated patients (p = 0.003).


The authors concluded that pleural effusion is associated with worse prognosis and lower responses to treatment with an immune checkpoint inhibitor.

No external funding was disclosed.


42P – Epaillard N, Benitez JC, Gorria T, et al. Pleural effusion is a negative prognostic factor for immunotherapy in non-small cell lung cancer (NSCLC): The PLUIE study. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...